³¹P spectroscopy of the human prostate gland in vivo using a transrectal probe

Abstract

Using a transrectal probe, good quality 31P magnetic resonance spectroscopy of the human prostate was performed safely, consistently, and in a reasonable amount of time (average of 60 min). Initial results indicate that transrectal 31P MRS has the ability to characterize the phosphorylated metabolites of normal, hyperplastic, and malignant prostates. This study demonstrated that malignant prostates are characterized by significantly decreased levels of phosphocreatine (PCr) and increased levels of phosphomonoesters (PME) as compared to healthy prostates.

31P MR spectroscopic imaging of the human prostate at 7 T: T1relaxation times, Nuclear Overhauser Effect, and spectral characterization

“…The near absence of signals in the phosphodiester region in the 7 T MR spectra of the prostate was in marked contrast with the phosphodiester region of low field strength in vivo 31 P MR spectra (including prostate spectra) (4,5,35). Those showed a high and broad peak in the phosphodiester region, which was generally assigned to GPC and GPE together, that is, free cytosolic compounds.…”

Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study

“…The assignments of the 'H resonances were made based on a previous knowledge of the phosphorylated metabolites observed in the respective tissues (16)(17)(18) and by comparison of chemical shifts and coupling constants of resonances with published values of known compounds at the same pH (19)(20)(21)(22)(23)(24)(25). Where assignments were ambiguous, resonance identities were confirmed by the addition of known standards (Sigma Chemical Co., St. Louis, MO).…”

Differentiation of human prostate cancer from benign hypertrophy by in vitro1H NMR

“…"P NMR spectroscopy has been used to study phosphorylated metabolites in prostate cancer in animals and humans (13)(14)(15)(16). These initial studies suggested that the ratios of phosphocreatine ( PCr) and phosphomonoesters ( PME) to adenosine triphosphate ( ATP) may differ in BPH and prostate cancer compared to normal tissue.…”